|
|
||
|
(State or other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
| Item 2.02. |
Results of Operations and Financial Condition.
|
| Item 7.01. |
Regulation FD Disclosure.
|
| Item 9.01. |
Financial Statements and Exhibits.
|
| (d) |
Exhibits
|
| 99.1 |
Press Release dated April 27, 2021
|
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
TURNING POINT BRANDS, INC.
|
|||
|
Dated: April 27, 2021
|
By:
|
/s/ Brittani N. Cushman
|
|
|
Brittani N. Cushman
|
|||
|
Senior Vice President, General Counsel and Secretary
|
|||

| ✔ |
Net sales increased 18.7% to $107.6 million
|
| ✔ |
Gross profit increased 28.6% to $53.3 million
|
| ✔ |
Net income increased $7.3 million to $11.8 million
|
| ✔ |
Adjusted EBITDA increased 57.4% to $28.0 million (see Schedule A for a reconciliation to net income)
|
| ✔ |
Diluted EPS of $0.57 and Adjusted Diluted EPS of $0.80 as compared to $0.22 and $0.51 in the year-ago period, respectively (see Schedule B for a reconciliation to
Diluted EPS)
|
| • |
$0.6 million of transaction expenses principally related to M&A activity as compared to $1.0 million in the year-ago period
|
| • |
Net Sales of $422 to $440 million (up from previous guidance of $412 to $432 million) which assumes:
|
| o |
Strong double-digit sales growth for Zig-Zag Products (up from previous guidance of double-digit sales growth)
|
| o |
High-single-digit sales growth for Stoker’s Products (unchanged)
|
| o |
Mid-to-low-single digit declines for NewGen Products (up from previous guidance of mid-single-digit sales declines), which includes single-digit declines for vape
distribution (up from previous guidance of double-digit declines) offset by growth in Nu-X
|
| • |
Adjusted EBITDA of $103 to $108 million (up from previous guidance of $99 to $105 million)
|
| • |
Stock compensation and non-cash incentive expense of $7 million
|
| • |
Cash interest expense of $19 million and GAAP interest expense of $22 million which no longer includes debt discount amortization related to the 2024 convertible
notes and reflects the recently priced senior secured notes
|
| • |
Effective income tax rate of 23% to 24%
|
| • |
Capital expenditures of $5 to $6 million
|
| • |
Net Sales of $103 to $109 million
|
|
Three Months Ended March 31,
|
||||||||
|
2021
|
2020
|
|||||||
|
Net sales
|
$
|
107,641
|
$
|
90,689
|
||||
|
Cost of sales
|
54,380
|
49,258
|
||||||
|
Gross profit
|
53,261
|
41,431
|
||||||
|
Selling, general, and administrative expenses
|
28,912
|
32,394
|
||||||
|
Operating income
|
24,349
|
9,037
|
||||||
|
Interest expense, net
|
4,486
|
3,309
|
||||||
|
Investment income
|
(25
|
)
|
(91
|
)
|
||||
|
Loss on extinguishment of debt
|
5,706
|
-
|
||||||
|
Net periodic income, excluding service cost
|
-
|
(87
|
)
|
|||||
|
Income before income taxes
|
14,182
|
5,906
|
||||||
|
Income tax expense
|
2,654
|
1,407
|
||||||
|
Consolidated net income
|
11,528
|
4,499
|
||||||
|
Net loss attributable to non-controlling interest
|
(255
|
)
|
-
|
|||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
11,783
|
$
|
4,499
|
||||
|
Basic income per common share:
|
||||||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.62
|
$
|
0.23
|
||||
|
Diluted income per common share:
|
||||||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.57
|
$
|
0.22
|
||||
|
Weighted average common shares outstanding:
|
||||||||
|
Basic
|
19,093,961
|
19,689,446
|
||||||
|
Diluted
|
22,665,067
|
20,106,800
|
||||||
|
Supplemental disclosures of statement of income information:
|
||||||||
|
Excise tax expense
|
$
|
8,789
|
$
|
5,041
|
||||
|
FDA fees
|
$
|
170
|
$
|
129
|
||||
|
ASSETS
|
March 31,
2021 |
December 31,
2020 |
||||||
|
Current assets:
|
||||||||
|
Cash
|
$
|
167,361
|
$
|
41,765
|
||||
|
Accounts receivable, net of allowances of $148 in 2021 and $150 in 2020
|
6,606
|
9,331
|
||||||
|
Inventories
|
98,351
|
85,856
|
||||||
|
Other current assets
|
24,866
|
26,451
|
||||||
|
Total current assets
|
297,184
|
163,403
|
||||||
|
Property, plant, and equipment, net
|
15,648
|
15,524
|
||||||
|
Deferred income taxes
|
-
|
610
|
||||||
|
Right of use assets
|
17,406
|
17,918
|
||||||
|
Deferred financing costs, net
|
464
|
641
|
||||||
|
Goodwill
|
159,808
|
159,621
|
||||||
|
Other intangible assets, net
|
78,945
|
79,422
|
||||||
|
Master Settlement Agreement (MSA) escrow deposits
|
31,477
|
32,074
|
||||||
|
Other assets
|
26,373
|
26,836
|
||||||
|
Total assets
|
$
|
627,305
|
$
|
496,049
|
||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
24,166
|
$
|
9,201
|
||||
|
Accrued liabilities
|
31,845
|
35,225
|
||||||
|
Current portion of long-term debt
|
5,000
|
12,000
|
||||||
|
Other current liabilities
|
205
|
203
|
||||||
|
Total current liabilities
|
61,216
|
56,629
|
||||||
|
Notes payable and long-term debt
|
424,802
|
302,112
|
||||||
|
Deferred income taxes
|
735
|
-
|
||||||
|
Lease liabilities
|
15,570
|
16,117
|
||||||
|
Other long-term liabilities
|
-
|
3,704
|
||||||
|
Total liabilities
|
502,323
|
378,562
|
||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders' equity:
|
||||||||
|
Preferred stock; $0.01 par value; authorized shares 40,000,000; issued and outstanding
shares -0-
|
-
|
-
|
||||||
|
Common stock, voting, $0.01 par value; authorized shares, 190,000,000; 19,576,821
issued shares and 19,059,120 outstanding shares at March 31, 2021, and 19,532,464 issued shares and 19,133,794 outstanding shares at December 31, 2020
|
196
|
195
|
||||||
|
Common stock, nonvoting, $0.01 par value; authorized shares, 10,000,000; issued and
outstanding shares -0-
|
-
|
-
|
||||||
|
Additional paid-in capital
|
102,879
|
102,423
|
||||||
|
Cost of repurchased common stock
|
||||||||
|
(517,701 shares at March 31, 2021 and 398,670 shares at December 31, 2020)
|
(15,924
|
)
|
(10,191
|
)
|
||||
|
Accumulated other comprehensive loss
|
(480
|
)
|
(2,635
|
)
|
||||
|
Accumulated earnings
|
34,357
|
23,645
|
||||||
|
Non-controlling interest
|
3,954
|
4,050
|
||||||
|
Total stockholders' equity
|
124,982
|
117,487
|
||||||
|
Total liabilities and stockholders' equity
|
$
|
627,305
|
$
|
496,049
|
||||
|
Three Months Ended March,
|
||||||||
|
2021
|
2020
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Consolidated net income
|
$
|
11,528
|
$
|
4,499
|
||||
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
|
Loss on extinguishment of debt
|
5,706
|
-
|
||||||
|
Gain on sale of property, plant, and equipment
|
(2
|
)
|
-
|
|||||
|
Depreciation expense
|
788
|
851
|
||||||
|
Amortization of other intangible assets
|
477
|
425
|
||||||
|
Amortization of deferred financing costs
|
604
|
552
|
||||||
|
Deferred income taxes
|
552
|
1,006
|
||||||
|
Stock compensation expense
|
1,498
|
455
|
||||||
|
Noncash lease expense
|
6
|
13
|
||||||
|
Gain on investments
|
(13
|
)
|
-
|
|||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable
|
2,735
|
2,596
|
||||||
|
Inventories
|
(12,461
|
)
|
1,784
|
|||||
|
Other current assets
|
1,283
|
(2,420
|
)
|
|||||
|
Other assets
|
464
|
(130
|
)
|
|||||
|
Accounts payable
|
14,882
|
3,210
|
||||||
|
Accrued postretirement liabilities
|
-
|
(27
|
)
|
|||||
|
Accrued liabilities and other
|
(3,806
|
)
|
1,913
|
|||||
|
Net cash provided by operating activities
|
$
|
24,241
|
$
|
14,727
|
||||
|
Cash flows from investing activities:
|
||||||||
|
Capital expenditures
|
$
|
(842
|
)
|
$
|
(877
|
)
|
||
|
Restricted cash, MSA escrow deposits
|
(14,920
|
)
|
-
|
|||||
|
Proceeds on the sale of property, plant and equipment
|
2
|
-
|
||||||
|
Net cash used in investing activities
|
$
|
(15,760
|
)
|
$
|
(877
|
)
|
||
|
Cash flows from financing activities:
|
||||||||
|
Proceeds from Senior Secured Notes
|
$
|
250,000
|
$
|
-
|
||||
|
Payments of 2018 first lien term loan
|
$
|
(130,000
|
)
|
$
|
(2,000
|
)
|
||
|
Settlement of interest rate swaps
|
(3,573
|
)
|
-
|
|||||
|
Payment of IVG note
|
-
|
(4,240
|
)
|
|||||
|
Payment of dividends
|
(958
|
)
|
(886
|
)
|
||||
|
Payments of financing costs
|
(6,614
|
)
|
(168
|
)
|
||||
|
Exercise of options
|
425
|
227
|
||||||
|
Redemption of options
|
(1,466
|
)
|
-
|
|||||
|
Common stock repurchased
|
(5,733
|
)
|
(2,627
|
)
|
||||
|
Net cash provided by (used in) financing activities
|
$
|
102,081
|
$
|
(9,694
|
)
|
|||
|
Net increase in cash
|
$
|
110,562
|
$
|
4,156
|
||||
|
Effect of foreign currency translation on cash
|
$
|
101
|
$
|
-
|
||||
|
Cash, beginning of period:
|
||||||||
|
Unrestricted
|
41,765
|
95,250
|
||||||
|
Restricted
|
35,074
|
32,074
|
||||||
|
Total cash at beginning of period
|
76,839
|
127,324
|
||||||
|
Cash, end of period:
|
||||||||
|
Unrestricted
|
167,361
|
99,406
|
||||||
|
Restricted
|
20,141
|
32,074
|
||||||
|
Total cash at end of period
|
$
|
187,502
|
$
|
131,480
|
||||
|
Three Months Ended
March 31, |
||||||||
|
2021
|
2020
|
|||||||
|
Net income attributable to Turning Point Brands, Inc.
|
$
|
11,783
|
$
|
4,499
|
||||
|
Add:
|
||||||||
|
Interest expense, net
|
4,486
|
3,309
|
||||||
|
Loss on extinguishment of debt
|
5,706
|
-
|
||||||
|
Income tax expense
|
2,654
|
1,407
|
||||||
|
Depreciation expense
|
788
|
851
|
||||||
|
Amortization expense
|
477
|
425
|
||||||
|
EBITDA
|
$
|
25,894
|
$
|
10,491
|
||||
|
Components of Adjusted EBITDA
|
||||||||
|
Other (a)
|
-
|
(87
|
)
|
|||||
|
Stock options, restricted stock, and incentives expense (b)
|
1,498
|
455
|
||||||
|
Transactional expenses (c)
|
607
|
1,049
|
||||||
|
FDA PMTA (d)
|
-
|
5,874
|
||||||
|
Adjusted EBITDA
|
$
|
27,999
|
$
|
17,782
|
||||
|
Three Months Ended
March 31, |
||||||||
|
2021
|
2020
|
|||||||
|
GAAP EPS
|
$
|
0.57
|
$
|
0.22
|
||||
|
Other (a)
|
-
|
(0.00
|
)
|
|||||
|
Loss on extinguishment of debt (b)
|
0.20
|
-
|
||||||
|
Stock options, restricted stock, and incentives expense (c)
|
0.05
|
0.02
|
||||||
|
Transactional expenses (d)
|
0.02
|
0.04
|
||||||
|
FDA PMTA (e)
|
-
|
0.22
|
||||||
|
Tax (expense) benefit (f)
|
(0.05
|
)
|
0.01
|
|||||
|
Adjusted diluted EPS
|
$
|
0.80
|
$
|
0.51
|
||||
|
Consolidated
|
Zig-Zag Products
|
Stoker's Products
|
NewGen Products
|
|||||||||||||||||||||||||||||
|
1st Quarter
2021 |
1st Quarter
2020 |
1st Quarter
2021 |
1st Quarter
2020 |
1st Quarter
2021 |
1st Quarter
2020 |
1st Quarter
2021 |
1st Quarter
2020 |
|||||||||||||||||||||||||
|
Net sales
|
$
|
107,641
|
$
|
90,689
|
$
|
41,004
|
$
|
28,914
|
$
|
29,255
|
$
|
26,495
|
$
|
37,382
|
$
|
35,280
|
||||||||||||||||
|
Gross profit
|
$
|
53,261
|
$
|
41,431
|
$
|
24,896
|
$
|
16,132
|
$
|
15,892
|
$
|
13,874
|
$
|
12,473
|
$
|
11,425
|
||||||||||||||||
|
Operating income
|
$
|
24,349
|
$
|
9,037
|
$
|
19,437
|
$
|
12,417
|
$
|
12,255
|
$
|
9,746
|
$
|
2,006
|
$
|
477
|
||||||||||||||||
|
Adjustments:
|
||||||||||||||||||||||||||||||||
|
Transactional expenses
|
607
|
1,049
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
|
FDA PMTA
|
-
|
5,874
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
|
Adjusted operating income
|
$
|
24,956
|
$
|
15,960
|
$
|
19,437
|
$
|
12,417
|
$
|
12,255
|
$
|
9,746
|
$
|
2,006
|
$
|
477
|
||||||||||||||||